Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761353 | 0.90 | TAAR1 (0.47) | TAAR1IDO1ALOX5HRH3DAO | |
| SCHEMBL15042385 | 0.83 | CA2 (0.43) | ALOX5CA1CA2CA9XIAP | |
| SCHEMBL5644026 | 0.82 | IDO1 (0.56) | TAAR1IDO1CA1CA2CA9 | |
| SCHEMBL23782510 | 0.82 | MMP9 (0.43) | CA1CA2CA9ALDH1A1NR3C1 | |
| SCHEMBL16666444 | 0.81 | CA1 (0.42) | TAAR1ALOX5CA1CA2CA9 | |
| SCHEMBL2284428 | 0.81 | TAAR1 (0.49) | TAAR1IDO1CA1CA2CA9 | |
| SCHEMBL2878336 | 0.81 | TAAR1 (0.49) | TAAR1IDO1CA1CA2CA9 | |
| SCHEMBL1246000 | 0.81 | CYP4F2 (0.47) | ALOX5CA1CA2CA9ALDH1A1 | |
| SCHEMBL858115 | 0.81 | TAAR1 (0.49) | TAAR1IDO1ALOX5CA1CA2 | |
| SCHEMBL2881422 | 0.81 | IDO1 (0.43) | IDO1CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | disclosed |
| US-20220064105-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2022-03-03 | — | — | US | disclosed |
| WO-2022043755-A2 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2022-03-03 | — | — | WO | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0714894-A1 | 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5521197-A | ANALGESICS USING SEROTONIN ANTAGONIST | ELI LILLY AND COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0256888-B1 | BENZOTHIAZEPINE VASODILATORS HAVING ARALKYL SUBSTITUTION | McNeilab, Inc. (US) | 1991-07-03 | — | — | EP | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
| US-4729994-A | Benzothiazepine vasodilators having aralkyl substitution | MCNEILAB, INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0163416-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | TAAR1 634/4885IDO1 559/4885ALOX5 2104/4885 |
| US-20220064105-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | EDNRA, EDNRB, FFAR2 | TAAR1 370/4885IDO1 662/4885ALOX5 940/4885 |
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | EDNRA, FFAR2, EDNRB | TAAR1 323/4885IDO1 892/4885ALOX5 842/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | TAAR1 634/4885IDO1 559/4885ALOX5 2104/4885 |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | EDNRA, EDNRB, FFAR2 | TAAR1 181/4885IDO1 589/4885ALOX5 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.